Ayurvedic anti-malaria drug trial at Dhanwantry soon

Tribune News Service

Advertisement

Chandigarh, May 19

After hydroxychloroquine, an anti-malarial drug, showed efficacy in treating Covid-19 patients, the government plans to check an ayurvedic anti-malaria drug for the same.

For this, Shri Dhanwantry Ayurvedic College and Hospital, Sector 46, here, is all set to initiate an exploratory clinical trial to evaluate the efficacy and safety of “Ayush-64” as adjunct treatment to standard of care for the management of mild to moderate Covid cases.

Memorandum signed

A memorandum of undertaking has been signed between the Central Council for Research in Ayurvedic Sciences, New Delhi, and Shri Dhanwantry Ayurvedic College and Hospital, Sector 46. The duration of the project will be six months and the work will be carried out on the hospital premises.

The trial of ayurvedic drug, “Ayush 64”, on Covid patients will be started from May 24. “Ayush 64” is a formulation that was prepared to fight against malaria.

Shri Dhanwantry Ayurvedic College and Hospital will provide infrastructure such as PPE kits, masks, sanitisers and other things required for the safety of patients and team taking care of Covid patients.

A memorandum of undertaking has been signed between the Central Council for Research in Ayurvedic Sciences (CCRAS), New Delhi, and Shri DhanwantryAyurvedic College and Hospital, Sector 46. The duration of the project will be six months and the work will be carried out on the hospital premises.

A standardised coded ayurvedic drug will be provided by the Central Council for Research in Ayurvedic Sciences for the clinical trial. The entire funding for the project

will be extended by the CCRAS through Central Ayurveda Research Institute for Respiratory Disorders, Patiala.